ClinicalTrials.gg
CompletedNCT00157079Updated Aug 24, 2021

Safety and Efficacy Study of a 10% Intravenous Immune Globulin Solution in Subjects With Primary Immunodeficiency Disorders

A Phase 3 interventional study of Immune Globulin Intravenous (Human), 10% in Primary Immunodeficiency Diseases (PID), Immune Thrombocytopenic Purpura (ITP) and Kawasaki Syndrome, sponsored by Baxalta now part of Shire. Completed at 11 sites in United States. Open to participants aged 24 Months and older. Per ClinicalTrials.gov, last updated 2021-08-24.

Sponsored by Baxalta now part of Shire (part of Takeda) · Phase 3, Interventional, and Treatment

From the registry’s dates

  • Primary completion was Dec 2003, 22 years 11 months ago, and no results have been posted to the registry.
  • Registered 3 years 2 months after the study started (first participant enrolled Jun 2002, registered Sep 2005).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
61
Allocation
Randomized
Ages
24 Months and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-19

Among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases — 2 open to participants now, 4 under way, 4 of them phase 3. Immunoglobulins, Intravenous · Primary Immunodeficiency Diseases.

Enrollment
4th of 26
61 · median 45
Started
2002
with 2 others
Phase 3
18 of 27
2 open now
Registered
1st of 27
by date
Lead sponsor
8 of 27
Baxalta now part of Shire

Among the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, this one is the 4th largest by enrollment of the 26 interventional ones that give a count, is one of 3 that started in 2002, is one of 18 in phase 3, and was the 1st registered.

Primary Immunodeficiency Diseases

211 studies on the registry are indexed under Primary Immunodeficiency Diseases; 51 are open to participants now.

Browse Primary Immunodeficiency Diseases studies →

Open to participants now

2 of the 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases are open now. Recruiting first, the newest first:

All 2 open studies →

About Immunoglobulins, Intravenous

Immunoglobulins, Intravenous: first FDA approval 1944 (Baygam, Gamastan S/D), first EMA approval 2006. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 35 Primary Immunodeficiency Diseases studies recruiting now, 12 (34%) set no upper age limit and 10 (29%) stop at 75 or younger; 28 take children under 18; 11 take healthy volunteers.

This study: 24 Months and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 27 studies testing Immunoglobulins, Intravenous in Primary Immunodeficiency Diseases, or all of them as a file.
02

Study summary

The purpose of this study is to assess the safety and efficacy of Immune Globulin Intravenous (Human), 10% (IGIV 10%) in subjects with primary immunodeficiency disorders.

03

Conditions studied

  • Primary Immunodeficiency Diseases (PID)
  • Immune Thrombocytopenic Purpura (ITP)
  • Kawasaki Syndrome

Keywords

  • PID
  • Immunodeficiency
  • Immune Thrombocytopenic Purpura (ITP)
  • Kawasaki syndrome
04

Who can participate

Ages eligible
24 Months and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Written obtained from either the subject or the subject's legally acceptable representative prior to any study-related procedures and study product administration
  • Diagnosis of a PID disorder as defined by World Health Organization criteria for which the subject has been receiving a regimen of IGIV infusions every 21 to 28 days over a period of at least 4 months pre-study at a dose of 300-600 mg/kg body weight
  • Subjects > 24 months of age
  • A negative serum pregnancy test for any female subject who is of .

Exclusion criteria

Exclusion Criteria:

  • Subjects sero-positive at enrollment for one or more of the following: surface antigen (HBsAg), antibodies to virus (HCV), antibodies to (HIV) Types 1 or 2
  • Subjects with levels of alanine amino transferase () and aspartate amino transferase (AST) > 2.5 times the for the testing laboratory. An AST > 2.5 times the upper limit of normal is allowable, if the ALT does not exceed the upper limit of the reference range for the testing laboratory
  • Subjects with neutropenia (defined as an >= 1,000/mm3)
  • Subjects with serum creatinine levels greater than two times the upper limit of normal for age and gender
  • Subjects with or a history of malignancy
  • Subjects who received any blood or blood product exposure other than an IGIV and/or immune serum globulin (ISG) preparation within the 6 months prior to study entry
  • Subjects with an ongoing history of or persistent reactions (urticaria, breathing difficulty, severe hypotension, or anaphylaxis) following IGIV and/or ISG infusions
  • Subjects with selective complete IgA deficiency
  • Subjects with moderate levels of anti-IgA antibodies (>150), or subjects with lower anti-IgA antibodies who are naive to IGIV treatment. (Subjects with lower levels of IgA antibodies, whom the investigators know to have tolerated IgA containing IGIV preparations in the past, may be included if the investigator is comfortable with this)
  • Subjects receiving antibiotic therapy for the treatment of infection within 30 days prior to enrollment
  • Subjects who receive prophylactic antibiotics as part of their care regimen
  • Subjects participating in another clinical study involving an product or device within 30 days prior to study entry
Terms in these criteria, in plain language(11)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

Hepatitis B tests

Hepatitis B is a virus that infects the liver. These are separate tests: HBsAg positive usually means a current infection (a recent vaccination can briefly cause it too); total anti-HBc (HBcAb) positive means an infection now or in the past; HBV DNA measures how much virus is in the blood.

Some studies accept a past infection if HBV DNA is undetectable, sometimes with antiviral medicine during the study. Check what this study allows.

Hepatitis C tests

Hepatitis C is a virus that infects the liver. An HCV antibody test can stay positive after an infection has cleared (and is occasionally positive without one); an HCV RNA test shows whether the virus is there now.

After treatment, hepatitis C counts as cured when HCV RNA is still undetectable 12 weeks or more after the treatment ended. Studies often accept people cured this way.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

ALT and AST (liver enzymes)

Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.

Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.

ULN (upper limit of normal)

The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.

“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.

Absolute neutrophil count (ANC)

The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.

It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Hypersensitivity

An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Crossover assignment
Enrollment
61 participants (actual)
06

What researchers measure

Primary outcomes

  1. Mean number of acute serious bacterial infections per participant per year

    Time frame: Throughout the study period of 18 months

07

Study locations

11 sites
  • Children´s Hospital Los Angeles
    Los Angeles, California 90027, United States
  • Stanford University Medical Center
    Stanford, California 94304-8786, United States
  • 1st Allergy and Clinical Research Center
    Englewood, Colorado 80112, United States
  • Allergy Associates of the Palm Beaches
    North Palm Beach, Florida 33408, United States
  • University of South Florida; Asthma, Allergy & Immunology CRU
    Tampa, Florida 33613, United States
  • Rush Presbyterian - St. Lukes Medical Center
    Chicago, Illinois 60612, United States
  • Children´s Hospital Boston
    Boston, Massachusetts 02115, United States
  • Allergy, Asthma & Immunology Assoc.
    Omaha, Nebraska 68124, United States
  • Asthma and Allergy Center
    Papillion, Nebraska 68046, United States
  • Montefiore Medical Center, Albert Einstein College of Medicine
    Bronx, New York 10461, United States
  • Pediatric Allergy/Immunology Associates
    Dallas, Texas 75230, United States
08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Jun 2002 to primary completion in Dec 2003, 17 months.

Of 25 phase 3 interventional studies under Primary Immunodeficiency Diseases, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 19 and three quarters within 41. This study's 17 months is below that.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 8, 2005
First posted
Sep 12, 2005
StartActual
Jun 25, 2002
Primary completionActual
Dec 16, 2003
CompletionActual
Dec 16, 2003
Last update
Aug 24, 2021
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Aug 24, 2021, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT00157079
Responsible party
Sponsor
First posted
Sep 12, 2005
Start date
Jun 25, 2002
Primary completion
Dec 16, 2003
Completion
Dec 16, 2003
Last update
Aug 24, 2021

Study contacts

Study Director
study director · Takeda

Oversight

FDA-regulated drug
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Aug 2021. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Immunoglobulins, Intravenous

Start the discussion